eFFECTOR Therapeutics Announces Closing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules [Yahoo! Finance]
eFFECTOR Therapeutics, Inc. (EFTR)
Company Research
Source: Yahoo! Finance
in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced that it has closed its previously announced registered direct offering with a new healthcare focused institutional investor for the purchase and sale of an aggregate of 1,488,834 shares of its common stock (or common stock equivalents in lieu thereof) and short-term warrants to purchase up to an aggregate of 1,488,834 shares of its common stock at an offering price of $10.075 per share of common stock (or common stock equivalent in lieu thereof) and accompanying short-term warrant priced at-the-market under Nasdaq rules. The short-term warrants are exercisable immediately upon issuance, have an exercise price of $9.95 per share and expire three and one-half years from the date of issuance. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. The gross proceeds to the Company from the offering were approximately $15 million, before deduct
Show less
Read more
Impact Snapshot
Event Time:
EFTR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EFTR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EFTR alerts
High impacting eFFECTOR Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
EFTR
News
- eFFECTOR Therapeutics to Participate in Upcoming Investor Conference [Yahoo! Finance]Yahoo! Finance
- eFFECTOR Therapeutics to Participate in Upcoming Investor ConferenceGlobeNewswire
- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $24.00 price target on the stock.MarketBeat
- eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
- eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateGlobeNewswire
EFTR
Earnings
- 3/25/24 - Miss
EFTR
Analyst Actions
- 3/28/24 - HC Wainwright
EFTR
Sec Filings
- 4/26/24 - Form ARS
- 4/26/24 - Form DEFA14A
- 4/26/24 - Form DEF
- EFTR's page on the SEC website